MARC BLAUSTEIN - BIO

Marc is a successful life sciences consultant, executive, and entrepreneur with more than 25 years of industry experience.  He provides leadership development, strategy and corporate development counsel to life science and biopharma companies to help executives and their organizations grow and succeed. Marc brings a unique combination of strategic insight and “been there” operational experience to business and leadership challenges. He is currently a Senior Fellow at the Tufts Center for the Study of Drug Development, where he researches and writes about the strategic issues driving the future of the life sciences industry.

Marc has held executive leadership positions in both public and private companies, including as CEO and co-founder. Most recently, he served as COO at Finch Therapeutics, where he directed key functions including finance, HR, facilities, IT, and program management. Prior to Finch, he was Head of Business Development at Guide Therapeutics, a leader in targeted delivery of gene therapies, which was acquired in 2021 for $440 million by Beam Therapeutics. Previously, he co-founded and served as CEO of multiple life sciences companies.  He served as CEO of NED Biosystems, a company developing a combination treatment for advanced solid tumor cancers.  Prior to that, he was co-founder and CEO of Akashi Therapeutics, a rare disease-focused company that he led from its inception through construction of a multi-product portfolio, generation of clinical data, and establishment of a $100 million strategic partnership with a mid-sized pharmaceutical company.  His prior experience encompasses leadership of key commercial, product development, business, and operations functions within biotechnology companies.  Previously, Marc held leadership roles at Dyax Corp (now Takeda) including Senior VP Manufacturing, Process, and Commercial Operations, and led development of the now-marketed product Kalbitor.  Prior to joining Dyax, Marc held business development and program management leadership roles at Alkermes, where he initiated and led the development program for the now-marketed product Vivitrol.  Earlier, Marc joined Genetics Institute (now Pfizer) to head business development within one of the firm’s business units.

Marc holds a Master’s Degree from Harvard University’s Kennedy School and BA in Biology from the University of Pennsylvania.  He is also a Chartered Financial Analyst (CFA) charterholder.